Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has completed the acquisition of Haleon plc’s Nicotinell brand and related NRT products, expanding its consumer healthcare portfolio. The deal, valued at GBP 458 million, brings Nicotinell and other local market-leading NRT brands into Dr. Reddy’s fold, enhancing its global OTC business presence. This strategic move aligns with the company’s growth in consumer healthcare, complementing recent ventures such as the partnership with Nestlé India.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
